Blocking antibodies, such as monalizumab (IPH2201, a first-in-class ICI that targets the NKG2A receptors), to NKG2A unleashed the reactivity of these effector cells resulting in tumor control in multiple mouse models and an early clinical trial [40–42]. The gene discussed is KLRC1; the disease is neoplasm.